FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Patrick Howson

CIO Atuka

Wednesday 4th February 2026

Aligning Preclinical InVivo models of Parkinson’s Disease (PD) with Biological Classifications of PD

9:15 am

Examine why models differ in their degree of predictive validity for symptomatic and disease modifying therapies
Where do current models of PD sit within biological classifications of PD?
What should next generation models of PD focus on?